Status: Recruiting
Asciminib Roll-over Study
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Participants needed: 347
Trial details
Phase: Phase 4Age: 7-100Biological sex: AllType: InterventionalSponsor: Novartis PharmaceuticalsUpdated: Jun 10, 2026Locations: 85
Eligibility criteria
Participant with PH+ CML or PH+ ALL currently receiving treatment with asciminib... [+1]
Participant has been discontinued from parent study treatment. [+8]